Have a website account?
for exclusive website content.
Advisory Committee Board
Submit Multimedia Files
Conflict of Interest
Human and Animal Rights
AME Editing Service
Peer Review Process
Focused Issues (Published)
Focused Issues (Ongoing)
Article Processing Charges
Publish Ahead of Print
Publish Ahead of Print
Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
Masaoki Ito, Carles Codony-Servat, Niki Karachaliou, Rafael Rosell
Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients
Ryosuke Chiba, Naoto Morikawa, Koichiro Sera, Kazuyuki Ishida, Hiromi Nagashima, Wataru Shigeeda, Hiroyuki Deguchi, Makoto Tomoyasu, Takako Hosokawa, Hajime Saito, Tamotsu Sugai, Kohei Yamauchi, Makoto Maemondo
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
Alex Martinez-Marti, Alejandro Navarro, Enriqueta Felip
Brain metastases in oncogene-driven non-small cell lung cancer
Makoto Nishino, Kenzo Soejima, Tetsuya Mitsudomi
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Natalie M. Andrews Wright, Glenwood D. Goss
Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer
Fabrizio Tabbò, Silvia Novello
Biomarker for personalized immunotherapy
Si-Yang Liu, Yi-Long Wu
Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms
Ali Fatehi Hassanabad
Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management
Yayi He, Caicun Zhou
Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain
Jose M. Pacheco, Drew Moghanaki
Is the game over for PD-1 inhibitors in
mutant non-small cell lung cancer?
Maria A. Velez, Timothy F. Burns
Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
Rui Li, Steven M. Dubinett
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Jose M. Pacheco
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?
Yiqing Huang, Robert J. Walsh, Ross A. Soo
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Biagio Ricciuti, Giuseppe Lamberti, Fausto Roila, Giulio Metro
Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors
Jyoti Malhotra, Salma K. Jabbour, Sharon Pine
Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more
Angel Moran, Megan E. Daly
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
Laura Le, Ritchell van Dams, Percy Lee
Improving outcomes for brain metastases in EGFR mutated NSCLC
Jennifer W. Carlisle, Suresh S. Ramalingam
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Andrew J. Piper, Kartik Sehgal, Daniel B. Costa, Deepa Rangachari
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
Alice Mogenet, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery
Tamar B. Nobel, Prasad S. Adusumilli, Daniela Molena
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Debora Bruno, Afshin Dowlati
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
Antonio Passaro, Filippo de Marinis
Erlotinib as standard adjuvant therapy for resectable
mutation-positive non-small cell lung cancer
Satomi Tanaka, Junji Uchino
Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
Maria Jove, Noelia Vilariño, Ernest Nadal
Can liquid biopsy-guided
-targeted therapy be a surrogate for the tissue-based standard approach?
The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer
Carme Obiols, Sergi Call, Ramon Rami-Porta
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Amy Lauren Cummings, Edward B. Garon
KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
Amy Lauren Cummings, Kate M. Santoso, Jonathan W. Goldman
For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)
Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
Katsuhiro Masago, Yoshitsugu Horio, Shiro Fujita, Yasushi Yatabe
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Pascale Tomasini, Laurent Greillier
Adjuvant EGFR tyrosine kinase inhibitors in
-mutant non-small cell lung cancer: still an investigational approach
Lung neuroendocrine tumors: a new addition to the evolving list of spread through air spaces
Hironori Uruga, Mari Mino-Kenudson